Enzymotec Ltd. Reports Commercial Introduction of Its Innovative Omega PC(TM) Advanced Fish Oil Product

MIGDAL HA'EMEQ, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the launch of Omega PC™, a new, premium fish oil-based omega-3 product.

Omega PC™ is a wild, cold fish extract, containing omega-3 fatty acids bound to phospholipids (PL) and triglycerides (TG). The first commercial sale of this innovative product took place last week in preparation for customer launch.

"We are very pleased with the launch of Omega PC™ and believe this will take us one step further towards creating a new golden standard for fish oil consumption," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd. "Our strategic partnership with Polar Omega enables two significant players in the global omega-3 market to create a product that will deliver new health benefits to consumers. We believe that this new advanced fish oil product should help drive growth in the Omega 3 fish oil market, which became stagnant due to commoditization and lack of innovation."

Omega PC™ offers the following benefits compared to current omega-3 fish oil:

  • Omega-3 fatty acids bound to phospholipids that have been shown to be absorbed better than triglyceride bound Omega-3
  • Better absorption leads to better efficacy and to higher accumulation of omega-3 fatty acids in target organs
  • The omega-3 oil in Omega PC™ better represents the omega-3 oil in wild cold water fish as it contains omega 3 fatty acids bound to both TG and phospholipids.
  • Reduced fishy burps.

The production of Omega PC™ follows the strictest sustainability protocols of the International Fishmeal and Fish Oil Organization (IFFO).

About Enzymotec Ltd.

Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio- active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.

Forward Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: we depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; a high proportion of the sales of our INFAT® product is sold to end users by a single company in China; we are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; we may be required to pay royalties on sales of our krill products in North America and Australia; we have in the past, and may in the future, become subject to litigation regarding intellectual property rights or other matters; our offering of products as ''medical foods'' in the United States may be challenged by regulatory authorities; we rely on our Swedish joint venture partner to manufacture INFAT®, and certain matters related to the joint venture are the subject of disagreement; we are dependent on a single facility that houses the majority of our operations; we may be impacted by delays in manufacturing as we expand our capacity; we may not be able to expand our production or processing capabilities or satisfy growing demand; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on February 13, 2014. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: ICR, LLC Katie Turner 646-277-1228 -or- John Mills 310-954-1105 John.Mills@icrinc.comSource:Enzymotec Ltd.